Merkel Cell Carcinoma (MCC) Market, Epidemiology Insights and Market Forecast Report 2030

1. Merkel Cell Carcinoma (MCC) Market Merkel Cell Carcinoma (MCC) is a rare, highly aggressive neuroendocrine cutaneous neoplasm with a variable clinical presentation. It is a predominantly dermal-based lesion composed of monotonous small round cells with scanty cytoplasm, often difficult to differentiate from small round cell tumors, metastatic small cell carcinoma, blastic hematologic malignancies, and melanoma. It is caused by ultraviolet (UV) light exposure, infection with HIV virus, autoimmune diseases (rheumatoid arthritis), and certain malignancies like chronic lymphocytic leukemia or lymphomas, which can profoundly suppress the immune system and may act as a causative agent in MCC. It is also associated with Merkel cell polyomavirus in more than 80% of cases. DelveInsight's "Merkel Cell Carcinoma Market Insights, Epidemiology, and Market Forecast 2030" report delivers an in-depth understanding of the Merkel Cell Carcinoma, historical and forecasted epidemiology as well as the Merkel Cell Carcinoma market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. The Merkel Cell Carcinoma market report provides current treatment practices, emerging drugs, Merkel Cell Carcinoma market share of the individual therapies, current and forecasted Merkel Cell Carcinoma market Size from 2017 to 2030 segmented by seven major markets. The Report also covers current Merkel Cell Carcinoma treatment practice/algorithm, market drivers, market barriers and unmet

2. medical needs to curate best of the opportunities and assesses the underlying potential of the market. Geography Covered: The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom) & Japan View full report @https://www.delveinsight.com/report-store/merkel-cell- carcinoma-market Merkel Cell Carcinoma Disease Understanding and Treatment Algorithm The DelveInsight Merkel Cell Carcinoma market report gives a thorough understanding of the Merkel Cell Carcinoma by including details such as disease definition, symptoms, causes, pathophysiology, diagnosis and treatment. Diagnosis In most people, the first sign of Merkel cell carcinoma is a small bump (nodule) on the skin. This bump is usually firm and appears either skin-colored or red-purple. It also tends to grow rapidly. Often, there no symptoms associated with the nodule. Based on the American Joint Committee, MCC is divided into 4 stages, stage I tumor size of ≤2 cm, and stage II >2 cm, stage III as regional nodal disease, and stage IV as metastatic disease. The incidence of MCC is generally higher in men than in women. Treatment Surgery is the primary treatment option for patients with loco-regional primary MCC. At all stages of MCC, physicians recommend complete excision of the primary tumor, verified by pathologic examination, after excision, if the risk of recurrence to the local lymph nodes is high, it is recommended that the lesion should be treated with a course of radiation therapy. This may destroy any cancer cells that are not detectable by physical exam and can help prevent recurrence of the disease. MCC is generally considered to be a chemotherapy-sensitive tumor, but responses are seldom durable. Chemotherapy is reserved for the treatment of metastatic MCC (stage IV), and there is a growing opinion that it is mostly indicated to palliate symptoms. Commonly used regimens include. Adjuvant radiation therapy was associated with better outcomes compared with adjuvant chemotherapy.

3. The choice of treatment depends on the location of the tumor and comorbidities, highlighting the acute unmet need for effective treatment options with good safety and tolerability profile. Merkel Cell Carcinoma Epidemiology Merkel Cell Carcinoma (MCC) tumors often, but not always, appear on sun-exposed areas of the body. The tumors are not nearly as distinctive as other skin cancers and can appear as a pearly pimple-like lump, sometimes skin-colored, red, purple or bluish-red, though they are rarely tender to the touch. The rapid speed at which they grow is what often causes patients and doctors to take notice. While MCC is about three times more likely to be deadly than melanoma, with early detection, MCC can be treated successfully. The Merkel Cell Carcinoma epidemiology division provide insights about historical and current Merkel Cell Carcinoma patient pool and forecasted trend for every seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken. View epidemiology insights https://www.delveinsight.com/report-store/merkel-cell-carcinoma- epidemiology-forecast Key Findings •As per “Skin Cancer Foundation”, Merkel cell carcinoma (MCC) is 40 times rarer than melanoma, with an estimated one case per 130,000 people in the US. • As of 2015, approximately 2500 persons per year are diagnosed with this cancer in the United States. • It dramatically increases approximately to 9.8 people per 100,000 in individuals more than 85 years of age. • There is a 100,000-fold difference between the risks of developing MCC for patients under the age of 30 compared to those who are greater than 85 years old. Merkel Cell Carcinoma Drug Chapters Various companies such as Morphogenesis,NantKwest,Kartos Therapeutics, Incyte Corporation, and others are involved in developing effective therapies for Merkel Cell Carcinoma and further progress in the research and development is likely to translate into a real improvement in the treatment options for MCC. Various immunotherapies such as Nivolumab (Bristol-Myers Squibb), INCMGA00012 (Incyte corporation), KRT 232 (Kartos Therapeutics), haNk and aNK cell of the report @

4. therapies (NantKwest), and others are being developed as the monotherapy as well as adjuvant therapies to treat the advanced stage MCC. Drug chapter segment of the Merkel Cell Carcinoma report encloses the detailed analysis of Merkel Cell Carcinoma marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the Merkel Cell Carcinoma clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases. View competitive insights of the report @https://www.delveinsight.com/report- store/merkel-cell-carcinoma-pipeline-insight Merkel Cell Carcinoma Market Outlook Merkel Cell Carcinoma (MCC) is an aggressive malignancy with frequent recurrences and a high mortality rate, although patient outcomes are generally more favorable if the patient is referred for treatment at an early stage. The treatment of MCC is based mainly on the stage of the disease and the overall health of the patient. The core treatments for MCC, along with surgical excision, are radiation and chemotherapy, but some revolutionary therapies have recently moved into the forefront. Significant progress has been made in the understanding of MCC tumor biology and immunology. Recent advances in the development of well-tolerated immunotherapy agents have the potential to provide effective treatment options for patients with advanced or recurrent MCC in the future. Immunotherapy with the PD1–PDL1 immune-checkpoint pathway is a key therapeutic target in reactivating immune responses against various types of cancers. Several lines of evidence indicate that targeting this pathway could be an effective approach in MCC. Despite major advances in the understanding of the carcinogenesis, biology, and immunology of Merkel Cell Carcinoma (MCC), as well as the breakthrough in the therapy of advanced-stage disease using immune-checkpoint inhibitors, additional progress is a prerequisite in this space. Although advances have been made recently in the MCC field, large gaps remain with regard to definitive biomarkers and prognostic indicators. In addition, there are several other immunotherapy approaches being investigated for MCC in clinical trials, with the infusion of immune cells (T-cells or Natural Killer cells). Initial results suggest a promising future for immunotherapies in the treatment of MCC. Various companies are vigorously working in this direction to provide the therapeutic options to fulfill these gaps, here onwards the future of MCC is hope to be changed in the forecast period.

5. The Merkel Cell Carcinoma market outlook of the report helps to build the detailed comprehension of the historic, current, Carcinoma markettrends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology. According to DelveInsight, Merkel Cell Carcinoma market in 7MM is expected to change in the study period 2017-2030. Related reports: • Merkel Cell Carcinoma Pipeline Insight, 2020 • Merkel Cell Carcinoma Epidemiology Forecast to 2030 About DelveInsight: DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end to end comprehensive solutions to improve their performance. Media Relations Contact: Kritika Rehani krehani@delveinsight.com and forecasted Merkel Cell